

Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Urothelial Bladder Carcinoma — Part 1 of a 2-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. In locally advanced or metastatic urothelial carcinoma, pembrolizumab is approved for the first-line treatment of which patient population?**
  - a. Only patients with a PD-L1 combined positive score  $\geq 10$
  - b. Only patients older than age 65
  - c. Only patients ineligible for platinum-containing chemotherapy**
  - d. All patients with locally advanced or metastatic urothelial carcinoma
- 2. Enfortumab vedotin has a boxed FDA warning for which of the following toxicities?**
  - a. Interstitial lung disease and pneumonitis
  - b. Ocular toxicity
  - c. Neutropenia and diarrhea
  - d. Stevens-Johnson syndrome and toxic epidermal necrolysis**
- 3. Which of the following antibody-drug conjugates includes a humanized anti-Trop-2 antibody linked to SN-38?**
  - a. Disitamab vedotin
  - b. Enfortumab vedotin
  - c. Sacituzumab govitecan**
- 4. Patients with metastatic bladder cancer undergoing treatment with erdafitinib are at increased risk of which of the following adverse events?**
  - a. Hyperphosphatemia
  - b. Ocular disorders
  - c. Onycholysis
  - d. All of the above**